Monday, 21 March 2011

EMA approves Fingolimod for RRMS

European Commission approves Fingolimod, the first oral multiple sclerosis treatment for use in the EU.
(1) Fingolimod is approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS. (2) Fingolimod showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year. (3) Two-year, placebo-controlled study demonstrated that Fingolimod significantly reduced the risk of disability progression. Click here to see a YouTube clip of Fingolimod's mode of action